SG11201908844YA - Vectors and compositions for treating hemoglobinopathies - Google Patents
Vectors and compositions for treating hemoglobinopathiesInfo
- Publication number
- SG11201908844YA SG11201908844YA SG11201908844YA SG11201908844YA SG 11201908844Y A SG11201908844Y A SG 11201908844YA SG 11201908844Y A SG11201908844Y A SG 11201908844YA SG 11201908844Y A SG11201908844Y A SG 11201908844YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- rule
- viii
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478375P | 2017-03-29 | 2017-03-29 | |
| US201762489149P | 2017-04-24 | 2017-04-24 | |
| PCT/US2018/025165 WO2018183692A1 (en) | 2017-03-29 | 2018-03-29 | Vectors and compositions for treating hemoglobinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908844YA true SG11201908844YA (en) | 2019-10-30 |
Family
ID=63677097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908844Y SG11201908844YA (en) | 2017-03-29 | 2018-03-29 | Vectors and compositions for treating hemoglobinopathies |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12703864B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3600448A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7228523B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110582305A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018243293A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019020322A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3057862A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269551A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201908844YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018183692A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| SG11201908844YA (en) * | 2017-03-29 | 2019-10-30 | Bluebird Bio Inc | Vectors and compositions for treating hemoglobinopathies |
| EP3942046A1 (en) * | 2019-03-22 | 2022-01-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Bifunctional vectors allowing bcl11a silencing and expression of an anti-sickling hbb and uses thereof for gene therapy of b- hemoglobinopathies |
| JP7853100B2 (ja) * | 2019-06-05 | 2026-04-28 | オーチャード セラピューティクス(ヨーロッパ)リミテッド | 真核細胞を修飾するための組成物及び方法 |
| JP7803014B2 (ja) * | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| CN117384967A (zh) * | 2020-04-24 | 2024-01-12 | 康霖生物科技(杭州)有限公司 | 一种核酸构建体 |
| EP4222271A4 (en) * | 2020-11-23 | 2025-07-30 | Intas Pharmaceuticals Ltd | LENTIVIRUS VECTOR GENE THERAPY-BASED DELIVERY FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5928638A (en) | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| US8101349B2 (en) | 1997-12-23 | 2012-01-24 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells and their methods of use II |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| ES2348868T3 (es) | 2002-12-13 | 2010-12-16 | Genetix Pharmaceuticals Inc. | Vectores retrovirales terapeuticos para terapia genica. |
| CA2566286A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| US20080051431A1 (en) | 2006-05-26 | 2008-02-28 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds in combination therapy |
| EP3031916B1 (en) | 2007-06-11 | 2017-06-07 | Takara Bio Inc. | Method for expression of specific gene |
| GB0713183D0 (en) | 2007-07-06 | 2007-08-15 | King S College London | Method |
| US20110294144A1 (en) | 2008-02-12 | 2011-12-01 | Kenichi Noguchi | Screening method |
| ES2738980T3 (es) | 2008-09-15 | 2020-01-28 | Childrens Medical Ct Corp | Modulación de BCL11A para el tratamiento de hemoglobinopatías |
| US20110294114A1 (en) | 2009-12-04 | 2011-12-01 | Cincinnati Children's Hospital Medical Center | Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells |
| WO2011072086A1 (en) | 2009-12-08 | 2011-06-16 | Hemaquest Pharmaceuticals, Inc. | Methods and low dose regimens for treating red blood cell disorders |
| WO2012073047A2 (en) | 2010-12-03 | 2012-06-07 | Genome Research Limited | Compositions and methods |
| WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
| DK2717922T3 (en) | 2011-06-10 | 2019-01-07 | Bluebird Bio Inc | GENERATIVE VECTORS FOR ADDRENOLEUCODYSTROPHY AND ADDRENOMYELONE EUROPE |
| CA2850484C (en) | 2011-09-30 | 2021-01-26 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| ES2708948T3 (es) | 2012-11-27 | 2019-04-12 | Childrens Medical Ct Corp | Elementos reguladores distales de bcl11a como dianas para la reinducción de la hemoglobina fetal |
| US10106816B2 (en) * | 2012-12-14 | 2018-10-23 | Case Western Reserve University | Genomic RNA packaging enhancer element |
| WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
| ES2721936T3 (es) | 2013-11-13 | 2019-08-06 | Childrens Medical Center | Regulación de la expresión genética mediada por las nucleasas |
| US10982339B2 (en) | 2014-04-25 | 2021-04-20 | C2Cnt Llc | Process for the production of ammonia from air and water |
| WO2015164739A1 (en) * | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Kappa/lambda chimeric antigen receptors |
| CN106794260B (zh) | 2014-04-25 | 2021-02-23 | 儿童医疗中心有限公司 | 治疗血红蛋白病的组合物和方法 |
| WO2015164759A2 (en) | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Mnd promoter chimeric antigen receptors |
| BR112017004349A2 (pt) | 2014-09-04 | 2017-12-05 | Memorial Sloan Kettering Cancer Center | terapia com gene de globina para o tratamento de hemoglobinopatias |
| US10383929B2 (en) * | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| KR102598130B1 (ko) | 2015-03-31 | 2023-11-02 | 글리코토페 게엠베하 | 글로빈 유전자 클러스터의 조절 요소를 포함하는 진핵생물 발현 벡터 |
| WO2016182893A1 (en) | 2015-05-08 | 2016-11-17 | Teh Broad Institute Inc. | Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof |
| EP4014996A1 (en) | 2015-08-31 | 2022-06-22 | Helixmith Co., Ltd | Anti-sialyl tn chimeric antigen receptors |
| GB201522243D0 (en) | 2015-12-16 | 2016-01-27 | Ucl Business Plc | Treatment |
| KR20250134722A (ko) | 2016-02-12 | 2025-09-11 | 블루버드 바이오, 인코포레이티드. | Vcn 인핸서 조성물 및 이의 사용 방법 |
| US11261441B2 (en) * | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| SG11201908844YA (en) * | 2017-03-29 | 2019-10-30 | Bluebird Bio Inc | Vectors and compositions for treating hemoglobinopathies |
-
2018
- 2018-03-29 SG SG11201908844Y patent/SG11201908844YA/en unknown
- 2018-03-29 JP JP2019553350A patent/JP7228523B2/ja active Active
- 2018-03-29 CN CN201880027694.4A patent/CN110582305A/zh active Pending
- 2018-03-29 EP EP18775163.1A patent/EP3600448A4/en active Pending
- 2018-03-29 BR BR112019020322-2A patent/BR112019020322A2/pt not_active Application Discontinuation
- 2018-03-29 CA CA3057862A patent/CA3057862A1/en active Pending
- 2018-03-29 AU AU2018243293A patent/AU2018243293A1/en not_active Abandoned
- 2018-03-29 WO PCT/US2018/025165 patent/WO2018183692A1/en not_active Ceased
-
2019
- 2019-09-23 IL IL26955119A patent/IL269551A/en unknown
-
2022
- 2022-01-28 US US17/587,999 patent/US12703864B2/en active Active
-
2023
- 2023-01-18 JP JP2023005869A patent/JP2023033551A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3057862A1 (en) | 2018-10-04 |
| EP3600448A1 (en) | 2020-02-05 |
| EP3600448A4 (en) | 2021-01-27 |
| JP7228523B2 (ja) | 2023-02-24 |
| WO2018183692A8 (en) | 2019-05-02 |
| AU2018243293A1 (en) | 2019-10-31 |
| US12703864B2 (en) | 2026-08-11 |
| WO2018183692A1 (en) | 2018-10-04 |
| IL269551A (en) | 2019-11-28 |
| JP2020511991A (ja) | 2020-04-23 |
| CN110582305A (zh) | 2019-12-17 |
| JP2023033551A (ja) | 2023-03-10 |
| BR112019020322A2 (pt) | 2020-04-28 |
| US20220259594A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201901494UA (en) | Acid-alpha glucosidase variants and uses thereof | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201907653QA (en) | Compositions and methods for enhanced gene expression | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201901066UA (en) | Novel alkaline stable immunoglobulin-binding proteins | |
| SG11201908393YA (en) | Modulators of pcsk9 expression | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201808812RA (en) | Novel aav8 mutant capsids and compositions containing same | |
| SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201407866XA (en) | Method for expression of heterologous proteins using a recombinant negative-strand rna virus vector | |
| SG11201900038QA (en) | Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter | |
| SG11201408054RA (en) | Pegylated oxm variants |